We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gyros Signs Distributor Agreements with Alpha Analytical, Spinco Biotech and HVD Vertriebs
News

Gyros Signs Distributor Agreements with Alpha Analytical, Spinco Biotech and HVD Vertriebs

Gyros Signs Distributor Agreements with Alpha Analytical, Spinco Biotech and HVD Vertriebs
News

Gyros Signs Distributor Agreements with Alpha Analytical, Spinco Biotech and HVD Vertriebs

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gyros Signs Distributor Agreements with Alpha Analytical, Spinco Biotech and HVD Vertriebs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Erik Walldén, CEO at Gyros, commented on the company’s selection: “Alpha is a well-established provider of analytical tools to the growing biopharmaceutical industry in Singapore. Both Spinco, a distributor with broad coverage of the Indian market, and HVD, well-known throughout the Middle East, Russia and Africa, have an excellent reputation for customer service. Such factors featured significantly in our choice.”

Mr. Walldén continued: “Following a successful year in which we increased our presence significantly in North America and Europe and established distributorships in Japan and Korea, we believe the time is right to continue to expand our global coverage. We look forward to a fruitful relationship with our new partners.”

Major biopharmaceutical companies and their service providers currently utilize the Gyros immunoassay platform to boost time-critical workflows and meet increasing regulatory demands in the development of biotherapeutics and vaccines. By reducing turnaround times and enabling scientists to make data-driven decisions based on high quality data, the Gyros platform increases overall productivity and efficiency. Advantages such as unattended running of samples and assay development, within days rather than months, ensure substantial time-saving for analysts. Working at nanoliter scale cuts sample consumption and significantly reduces the cost of preclinical studies. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

Advertisement